When performed in tandem, two molecular biology laboratory tests distinguish, with near certainty, pancreatic lesions that mimic early signs of cancer but are benign.
Molecular classification of the four distinct subtypes of gastric cancer could potentially shape tailored treatment options by helping to predict survival outcomes and patients' response to chemotherapy.
Researchers at the University of Wisconsin School of Medicine and Public Health determined that people with a certain type of insurance policy were more likely to be screened for colorectal cancer.
Findings from a phase III clinical trial for advanced lung cancer patients could help oncologists better predict which patients are likely to receive the most benefit from immunotherapy as a first-line treatment based on the unique molecular characteristics of their tumor, according to a new study reported by a global team led by David Carbone of Ohio State University Comprehensive Cancer–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
Agios Pharmaceuticals Inc. published efficacy and safety data from the ongoing phase I/II dose-escalation and expansion study evaluating investigational oral Idhifa (enasidenib) in patients with relapsed or refractory acute myeloid leukemia and an isocitrate dehydrogenase-2 mutation.
Merck KGaA, which operates its biopharmaceutical business as EMD Serono in the U.S. and Canada, and Pfizer Inc. said the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended the approval of avelumab (Bavencio) as a monotherapy for the treatment of adult patients with metastatic Merkel cell carcinoma.
Stand Up To Cancer is supporting a translational research team to explore how chimeric antigen receptor T-cell therapy, which has been applied in blood cancers, can be applied to pancreatic cancer, the American Association for Cancer Research, SU2C's Scientific Partner, announced.
Bristol-Myers Squibb Co. said FDA has expanded the indication for Yervoy (ipilimumab) injection for intravenous use to now include the treatment of unresectable or metastatic melanoma in pediatric patients 12 years of age and older.
Bristol-Myers Squibb Co. said FDA accepted its supplemental Biologics License Applications to update Opdivo (nivolumab) dosing to include 480 mg infused over 30 minutes every four weeks for all currently approved monotherapy indications.
Carlos Arteaga, a breast cancer expert, was named director of the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern Medical Center. His appointment begins Sept. 1. Arteaga comes to UT Southwestern from the Vanderbilt-Ingram Cancer Center, where he has been on faculty since 1989.
